Tesamorelin Peptide Explained: Benefits, Risks & Myths

Image: Chemical structure of Egrifta (tesamorelin for injection) for subcutaneous use, by Vaccinationist, adapted from U.S. prescribing information, Public Domain, via Wikimedia Commons.

It’s amazing how much the conversation around peptides has changed, even here in Northeast Nebraska.

A year or two ago, I could mention the word peptide and get a blank stare. Maybe it would trigger some vague memory from the inner recesses of high school chemistry class, but that was about it.

Now? I kid you not, I’m getting patients left and right asking me about specific peptides by name.

“What do you think about BPC-157?”

“Have you heard of CJC-1295?”

And the focus of this article: “What about tesamorelin?”

People are doing their homework. They’re listening to podcasts, watching videos, reading about peptides online and coming into the office with very specific questions. Not only that, they’re seeing the results their friends, family members and coworkers are getting and wondering whether peptides might make sense for them, too.

I actually like that.

But it also means we have to separate what a peptide has actually been shown to do from what somebody on social media says it can do.

So with that subtle disclaimer out of the way, tesamorelin gets a lot of attention because of its effects on abdominal fat, particularly a type of fat called visceral fat. There’s legitimate clinical research behind it, which makes it much more interesting to me than simply saying, “Here’s another peptide people are excited about.”

(As I write this, there’s over 100 research papers published on it.)

But there are also some misconceptions worth clearing up.

Tesamorelin is not Ozempic. It isn’t simply a fat-burning injection. And it isn’t FDA-approved as a general weight-loss or anti-aging drug.

So what does it actually do?

What Is Tesamorelin?

Tesamorelin is a synthetic version of a hormone your body already makes called growth hormone-releasing hormone, usually shortened to GHRH.

GHRH comes from the hypothalamus in the brain and essentially tells your pituitary gland to release growth hormone.

Tesamorelin mimics that signal.

In very simplified terms, the pathway looks something like this:

Tesamorelin → pituitary gland → growth hormone → IGF-1 → effects on metabolism and body composition

One distinction I want to make right away is that tesamorelin is not human growth hormone.

If someone takes recombinant human growth hormone, they are giving the body growth hormone directly.

Tesamorelin works farther upstream by signaling the pituitary gland to release more of the growth hormone the body produces itself.

That difference is one reason tesamorelin has attracted so much interest in metabolic medicine.

Tesamorelin’s FDA-Approved Use

Tesamorelin isn’t a new compound that suddenly appeared because peptides became popular.

The FDA first approved it in 2010 for reducing excess abdominal fat in adults with HIV-associated lipodystrophy.

Lipodystrophy refers to abnormal changes in how the body stores fat. Some people with HIV, particularly those treated with certain antiretroviral medications, can develop significant accumulation of fat deep inside the abdomen.

That’s the population in which tesamorelin has been most extensively studied.

But tesamorelin is not FDA-approved for general weight loss or obesity treatment.

The current FDA prescribing information actually describes tesamorelin as having a weight-neutral effect and specifically states that it isn’t indicated for weight-loss management.

That may sound strange when we’re talking about a medication that reduces abdominal fat, but it makes more sense once you understand the type of fat we’re talking about.

Not All Belly Fat Is the Same

When people say they want to lose belly fat, they’re usually talking about everything around the midsection as if it’s one thing.

Physiologically, it isn’t.

There are two major types of abdominal fat worth understanding.

Subcutaneous Fat

Subcutaneous fat sits directly underneath the skin.

It’s the softer fat you can grab or pinch around your stomach, hips or thighs.

Visceral Fat

Visceral fat sits much deeper inside the abdomen, surrounding organs such as the liver and intestines.

You can’t pinch visceral fat because it isn’t sitting right underneath the skin.

And from a health perspective, excess visceral fat is more concerning.

Higher levels of visceral fat are associated with insulin resistance, abnormal blood lipids and greater cardiometabolic risk.

What Does the Research on Tesamorelin Show?

Clinical trials suggest that tesamorelin can preferentially reduce visceral adipose tissue, rather than simply causing someone to lose weight everywhere. And this isn’t based on one tiny study.

Tesamorelin has been evaluated in multiple randomized, placebo-controlled clinical trials.

In one 12-month study involving 404 adults with HIV and excess abdominal fat, visceral fat decreased by approximately 10.9% after six months in participants receiving tesamorelin, compared with just 0.6% in those receiving placebo.

People who continued tesamorelin for the full 12 months experienced an approximately 18% reduction in visceral fat.

Researchers also saw improvements in waist circumference and trunk fat. (You can access the study here.)

Another randomized trial involving 412 people found that visceral fat decreased 15.2% in the tesamorelin group while actually increasing 5% in the placebo group.

Triglycerides and the ratio of total cholesterol to HDL cholesterol also improved in the tesamorelin group. Before thinking, “Great, I can toss my statin,” not so fast. Tesamorelin isn’t a cholesterol medication, and an improvement in a few lipid markers doesn’t mean it has been shown to reduce heart attacks and strokes the way established cardiovascular therapies have.

Anyway, more recently, a 2026 meta-analysis pooling five randomized controlled trials found reductions in visceral fat, trunk fat, waist circumference and liver fat, along with an increase in lean body mass.

But most of this research has been conducted in people with HIV-associated lipodystrophy.

So I don’t think it’s responsible to take those numbers and tell an otherwise healthy patient, “You will lose 15% or 18% of your visceral fat.”

Is Tesamorelin a Weight-Loss Drug?

Some people have read or seen social posts that claim that tesamorelin reduces abdominal fat.

So it’s gotta be a weight-loss peptide, right?

Not exactly.

Medications such as GLP-1 receptor agonists [examples: semaglutide (Ozempic/Wegovy), liraglutide (Victoza/Saxenda), and dulaglutide (Trulicity)] can dramatically affect appetite, food intake and total body weight.

However, tesamorelin works through a completely different pathway. Not only that, a person could potentially reduce visceral fat while seeing relatively little change on the bathroom scale.

So instead of a weight loss peptide, it’s more of a “changing what’s under the hood” peptide.

Tesamorelin For Muscle and Lean Body Mass?

That study I mentioned earlier suggests that along with reductions in visceral fat, tesamorelin led to increases in lean body mass.

In fact, the meta-analysis from earlier this year found an average increase in lean body mass of about 1.4 kilograms, or roughly three pounds, across the trials it analyzed.

But don’t think that this peptide is the same as resistance training, adequate protein, and proper nutrition.

More realistically, tesamorelin may alter some of the hormonal and metabolic signals influencing body composition.

How Tesamorelin Affects The Liver

Researchers have looked at whether tesamorelin affects hepatic fat, which simply means fat stored in the liver.

In a randomized clinical trial at Massachusetts General Hospital, people living with HIV and excess abdominal fat received either tesamorelin or placebo for six months.

Those receiving tesamorelin had significant reductions in both visceral abdominal fat and liver fat.

Researchers later conducted a 12-month randomized trial involving people with HIV and fatty liver disease.

Tesamorelin produced a significantly greater decrease in liver fat than placebo, with researchers calculating an approximately 37% relative reduction in hepatic fat fraction from baseline attributable to treatment.

Visceral fat and fat stored in the liver are both closely tied to metabolic health.

But this doesn’t mean tesamorelin is an FDA-approved fatty liver treatment for the general population.

However, the research provides us another clue about how strongly the growth hormone pathway can influence where the body stores fat.

Do You Need To Keep Taking Tesamorelin?

Short answer: Maybe. You see, the effects may not stick around once treatment stops. In the 12-month study I mentioned earlier, participants initially received either tesamorelin or placebo for six months. Then some of the people taking tesamorelin were switched to placebo.

The visceral fat they had lost rapidly began returning after tesamorelin was discontinued.

That tells us that tesamorelin can influence a biological pathway while you’re using it, but that doesn’t necessarily mean it permanently changes whatever caused the fat accumulation in the first place.

This is why I don’t think peptide therapy should ever become a substitute for addressing someone’s overall metabolic health.

If we’re concerned about visceral fat, I also want to know what’s happening with insulin sensitivity, blood sugar, nutrition, strength, sleep, hormones and activity level.

A peptide is one tool, not the toolbox.

What Are the Risks and Side Effects?

Tesamorelin affects the growth hormone/IGF-1 pathway, so I don’t consider this something people should experiment with casually.

Potential side effects include:

• injection-site reactions
• joint pain
• muscle pain
• swelling or fluid retention
• tingling or numbness
• carpal tunnel-type symptoms

Tesamorelin also raises IGF-1, sometimes substantially.

Because prolonged elevation of IGF-1 has uncertain long-term implications, the FDA recommends monitoring IGF-1 during treatment.

Blood glucose is another consideration.

Growth hormone can affect glucose metabolism, so current prescribing information recommends evaluating glucose before and during therapy. Tesamorelin may contribute to glucose intolerance or diabetes in some patients.

There are also people for whom tesamorelin is clearly inappropriate.

The current FDA label lists contraindications including active malignancy, pregnancy and certain conditions that disrupt the hypothalamic-pituitary axis.

This is one of those areas where I think the way we talk about peptides makes a big difference.

They’re sometimes presented online almost like supplements, which, of course, they are not!

Peptides deliberately alter biological signaling pathways, and that deserves medical screening, appropriate dosing and follow-up.

Is Tesamorelin an Anti-Aging Peptide?

You’ll absolutely see tesamorelin described this way online, but I think we have to be much more careful with that language.

Growth hormone production naturally declines as we get older.

And because growth hormone influences body composition, fat metabolism, muscle and other tissues, it’s easy to make the leap that increasing growth hormone signaling must somehow reverse aging.

But with tesamorelin, that’s a much bigger claim than the science currently supports.

Should I Take Tesamorelin?

Possibly. But I wouldn’t start with the peptide. I’d start with you. What are we actually trying to change? Are you concerned about visceral fat? Have you gained weight despite doing many of the right things? Are you losing muscle as you get older? Is insulin resistance part of the picture? Are hormones changing?

Once we understand what’s happening physiologically, then we can decide which tools make sense.

Sometimes peptide therapy may be one of them.

That’s why I’m excited that patients are asking me about peptides.

I just want the conversation to go one step further than:

“I heard this one is good. Can I get it?”

When you work with a functional medicine practitioner like yours truly, the better question is:

“Does this particular peptide make sense for what is happening in my body?”